

# Summary:

## IMI consultation workshop on advanced therapies

**Magda Gunn**

29.09.2016 • IMI Stakeholder Forum 2016 • Brussels, Belgium

# Objectives of the consultation workshop on advanced therapies

The goal of this workshop is to assess the input collected in **previous consultations**, and **draw conclusions** to inform the development of an **IMI ATMP portfolio of projects** that could be launched from 2017 onwards.

# Highlights of the discussion

- ATMP – young, very dynamic and also very complex field
- Efforts dominated by academia and biotech – challenges in translation from POC to ultimately commercialisation
- Industry is interested but not yet very engaged
- Encouraging messages from regulatory and HTA
  - Regulation exist and practical application allows for feasibility based adaptability
  - Existing HTA tools are appropriate but consideration needs to be given to areas of uncertainty
  - Need for adequate payment/reimbursement models

# Deliverables

- Collaboration of all the key public and private stakeholders as well as patients
- Education and training for all stakeholders including raising public awareness
- Learn from what has already be done – pool, link & explore data, cohorts
- Abandon the old fashioned approach – instead use PPP whole system approach to define fit for purpose dynamics for ATMP development
- Pilot studies – tech transfer, GMP, manufacturing, product development business models
- Focus on diseases with important unmet medical need